Globus Medical reported second-quarter 2026 results with revenue of $789.61M and diluted EPS of $1.1, while net income declined to $151.57M versus the year-ago quarter, reflecting continued top-line growth alongside margin and integration-related pressures.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$789.61M$745.34M5.9% | Net income²$151.57M$202.85M(25.3%) | Diluted EPS³$1.1$1.49(26.2%) |
¹ Reported as “Net sales”. ² Reported as “Net income/(loss)”. ³ Reported as “Diluted earnings per share”.
Business Highlights
- Revenue growth was driven by Musculoskeletal Solutions and contributions from the Nevro acquisition, with year-to-date net sales up 15.3% through June 30, 2026.
- Geographic mix shifted favorably: U.S. sales rose 12.8% while international revenue increased 25.8%, led by EMEA and Latin America.
- Product momentum came from spine implantable devices and neuromonitoring, alongside increased adoption of Enabling Technologies.
- Operationally, the company completed Nevro merger integration activities, including inventory and intangible asset recognition and measurement-period adjustments.
- Gross margin benefited in part from the absence of a prior-year inventory step-up, though freight and depreciation pressures were noted.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.